Jefferies Upgrades GSK to Buy, Raises Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Peter Welford has upgraded GSK (NYSE:GSK) from Hold to Buy and increased the price target from $38.5 to $48, indicating a positive outlook for the company's stock.
January 03, 2024 | 10:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies has upgraded GSK from Hold to Buy and raised the price target to $48, suggesting a bullish stance on the stock's future performance.
Analyst upgrades typically lead to a positive short-term reaction in the stock market as they suggest improved fundamentals or future prospects for the company. The increase in price target by Jefferies reflects a significant potential upside from the previous target, which may attract investors and drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100